NMD Pharma Ignaseclant Phase 2a CMT Trial Shows Muscle Strength Benefits
NMD Pharma reported Phase 2a trial data showing ignaseclant improved muscle strength and motor function in adults with Charcot-Marie-Tooth disease, with benefits lasting seven days after treatment. The study met key secondary endpoints but missed its primary endpoint of six-minute walk test improvement. The drug has received FDA orphan drug designation for CMT.